Biocon has made a bold move. Its Denosumab biosimilars—Vevzuo and Evfraxy—have just been approved by the UK MHRA. This is big. It puts the Indian biopharma giant in the spotlight, once again proving that world-class science can come from India.
What is Vevzuo for?
Vevzuo is designed to help cancer patients with bone damage. It prevents serious issues like fractures, spinal cord compression, and surgeries caused by bone problems in people with advanced cancer that has spread to the bones.
It’s also approved for patients—both adults and adolescents—suffering from a giant cell tumour of bone, when surgery is too risky or not possible.
And what about Evfraxy?
Evfraxy is all about bone strength. It’s made for treating osteoporosis in postmenopausal women and in men who have a high risk of bone fractures. Clinical trials showed it reduces the risk of hip, spine, and other fractures.
There’s more. Evfraxy also treats bone loss in men with prostate cancer who are on hormone therapy. Plus, it’s helpful for people on long-term steroid treatment, which often weakens bones.
Just as good as the original
Both biosimilars—Vevzuo and Evfraxy—have been tested in clinical trials. The results? Their safety and effectiveness are on par with the original Denosumab. That’s a major green flag.
Also Read Biocon Eyes Early Lead in Canada’s Generic Wegovy, Ozempic Market
Already a hit in Europe
Before the UK approval, Biocon had already received a go-ahead from the European Commission. That means these drugs can be sold across all EU and EEA countries. With the UK now joining the list, Biocon is clearly expanding its global footprint.
Why this matters
This approval is more than a regulatory win. It’s a big moment for affordable healthcare. Denosumab is a costly treatment. Biocon’s biosimilars offer a cheaper, high-quality option for patients in need. It’s not just about making medicine. It’s about making an impact.
Biocon’s global ambition
Biocon is not new to the game. The company has been pushing boundaries in cancer, diabetes, and autoimmune disease treatment for years. With the UK MHRA nod, it has once again shown the world that Indian biotech can lead the way.
Also Read Biocon Gets EU Greenlight, Delivers Breakthrough Denosumab Biosimilars
